These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 8654133

  • 1. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
    Ganne-Carrié N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP.
    Dig Dis Sci; 1996 Jun; 41(6):1054-6. PubMed ID: 8654133
    [Abstract] [Full Text] [Related]

  • 2. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H, Chawla Y.
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
    [Abstract] [Full Text] [Related]

  • 3. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.
    Caraceni P, Santi L, Mirici F, Montanari G, Bevilacqua V, Pinna AD, Bernardi M.
    Dig Liver Dis; 2011 Mar; 43(3):242-5. PubMed ID: 20833118
    [Abstract] [Full Text] [Related]

  • 4. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
    Piano S, Morando F, Fasolato S, Cavallin M, Boscato N, Boccagni P, Zanus G, Cillo U, Gatta A, Angeli P.
    J Hepatol; 2011 Aug; 55(2):491-6. PubMed ID: 21334405
    [Abstract] [Full Text] [Related]

  • 5. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.
    Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF.
    Eur J Gastroenterol Hepatol; 2002 Feb; 14(2):153-8. PubMed ID: 11981339
    [Abstract] [Full Text] [Related]

  • 6. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC, REVERSE Study Investigators.
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [Abstract] [Full Text] [Related]

  • 7. Results of pretransplant treatment of hepatorenal syndrome with terlipressin.
    Solà E, Cárdenas A, Ginès P.
    Curr Opin Organ Transplant; 2013 Jun; 18(3):265-70. PubMed ID: 23652609
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Terlipressin in hepatorenal syndrome.
    Mazur JE, Cooper TB, Dasta JF.
    Ann Pharmacother; 2011 Mar; 45(3):380-7. PubMed ID: 21386023
    [Abstract] [Full Text] [Related]

  • 11. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
    Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, Le Moine O.
    Acta Gastroenterol Belg; 2001 Mar; 64(1):15-9. PubMed ID: 11322061
    [Abstract] [Full Text] [Related]

  • 12. Terlipressin. Type I hepatorenal syndrome: an extra window of time before liver transplantation.
    Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17171813
    [Abstract] [Full Text] [Related]

  • 13. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
    Fabrizi F, Dixit V, Messa P, Martin P.
    Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
    [Abstract] [Full Text] [Related]

  • 14. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.
    Restuccia T, Ortega R, Guevara M, Ginès P, Alessandria C, Ozdogan O, Navasa M, Rimola A, Garcia-Valdecasas JC, Arroyo V, Rodés J.
    J Hepatol; 2004 Jan; 40(1):140-6. PubMed ID: 14672625
    [Abstract] [Full Text] [Related]

  • 15. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.
    Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M.
    Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1363-8. PubMed ID: 12468959
    [Abstract] [Full Text] [Related]

  • 16. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
    Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R.
    J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
    [Abstract] [Full Text] [Related]

  • 17. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P, TAHRS Investigators.
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [Abstract] [Full Text] [Related]

  • 18. Review article: future indications for terlipressin therapy.
    Lebrec D.
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():65-7; discussion 68. PubMed ID: 15335406
    [Abstract] [Full Text] [Related]

  • 19. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.
    Wang H, Liu A, Bo W, Feng X, Hu Y.
    Medicine (Baltimore); 2018 Apr; 97(16):e0431. PubMed ID: 29668606
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.